The present approach to systematic cancer therapy.
D000470:Alkaloids / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D004247:DNA / Q000037:antagonists & inhibitors; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D008937:Mitomycins / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D009603:Nitroso Compounds / Q000627:therapeutic use; D011506:Proteins / Q000037:antagonists & inhibitors; D011687:Purines / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000037:antagonists & inhibitors; D012313:RNA / Q000037:antagonists & inhibitors
D000470:Alkaloids; D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D006728:Hormones; D008937:Mitomycins; D009603:Nitroso Compounds; D011506:Proteins; D011687:Purines; D011743:Pyrimidines; D012313:RNA; D004247:DNA; D001215:Asparaginase